Why Psilocybin Is Federally Illegal Despite Proven Medical Value

Psychedelic Law & Policy

134 registered clinical trials

As of 2024, 134 interventional psilocybin trials across 54 potential indications have been registered on ClinicalTrials.gov. Zero have received FDA marketing approval.

Norring et al., Drug Design, Development and Therapy, 2024

0 approvals

despite 134 registered clinical trials across 54 potential indications

71% response rate

Johns Hopkins RCT of psilocybin-assisted therapy for major depression

N=233

participants in the largest psilocybin RCT to date — published in the New England Journal of Medicine

Norring et al., Drug Design, Development and Therapy, 2024

View as image ↗

In 2021, the New England Journal of Medicine published a head-to-head trial. Psilocybin versus escitalopram, one of the most widely prescribed antidepressants, in 59 patients with major depression. Psilocybin matched the drug on the trial's primary outcome. On six of the secondary measures, psilocybin performed better.

That same year, the Journal of the American Medical Association published a Johns Hopkins trial where 71% of participants met responder criteria at the four-week mark after psilocybin-assisted therapy for major depressive disorder.

Psilocybin remains a Schedule I controlled substance under US federal law. Schedule I is reserved for substances the government classifies as having high abuse potential, no accepted medical use, and no safe level of use under medical supervision.

This article takes each of those three criteria and examines what the clinical research literature says about them directly. The broader history of how psilocybin ended up at Schedule I, and what the legal rescheduling pathways look like, is covered in Psilocybin's Schedule I Status: History and Controversy.

The Three Legal Reasons: What Schedule I Classification Actually Claims

A Schedule I controlled substance is one that meets three criteria under the Controlled Substances Act:

1. High potential for abuse — meaning the substance is more likely to be misused than substances in lower schedules
2. No currently accepted medical use in treatment in the United States — meaning the FDA has not approved it for any medical indication
3. Lack of accepted safety for use under medical supervision — meaning there is no safe way to use it even in a supervised clinical setting

These criteria are the legal basis for Schedule I placement. They are also the basis for challenging that placement, because if any criterion is empirically refuted, the classification can be argued as scientifically unsupported.

For a full explanation of how these criteria work within the CSA's legal framework, including the eight statutory scheduling factors and the three rescheduling pathways, see The Controlled Substances Act and Psilocybin: Legal Framework.

What follows is a point-by-point examination of each criterion against the available evidence.

Criterion 1 — High Abuse Potential: What Johnson's 8-Factor Analysis Found

In 2018, a group of pharmacologists at Johns Hopkins and the University of Maryland published a paper in Neuropharmacology specifically to apply the CSA's eight statutory scheduling factors to psilocybin. The authors — Johnson, Griffiths, Hendricks, and Henningfield — are among the most cited researchers in the psychedelic pharmacology field.

Their conclusion, stated directly in the abstract: psilocybin has low abuse potential according to the criteria defined by the Controlled Substances Act.^[1]

The relevant factors from that analysis:

Physical dependence potential: psilocybin produces no documented withdrawal syndrome. People who stop taking it do not experience the physiological withdrawal that occurs with opioids, alcohol, benzodiazepines, or other high-abuse-potential substances. There is no documented evidence of physical dependence.^[1]

Compulsive-use patterns: psilocybin users do not, as a documented pattern, take it compulsively. Animal models of addiction — where subjects self-administer a substance repeatedly under conditions designed to trigger addiction — show that psilocybin is not self-administered in the way cocaine, methamphetamine, opioids, or alcohol are.^[1]

The pharmacological foundation for these conclusions was established by Nichols in a comprehensive 2016 review of classical psychedelics in Pharmacological Reviews. Nichols documented that psilocybin has no known lethal dose in humans — there are no confirmed deaths attributable to psilocybin toxicity — and that it produces no physical withdrawal syndrome, distinguishing it pharmacologically from every substance currently in Schedule I or II that is there specifically for its addiction potential.^[2]

Johnson and colleagues' analysis is particularly notable because the authors did not argue that psilocybin has zero risk or zero misuse potential. They acknowledged that psilocybin can produce adverse psychological reactions and that misuse occurs. Their argument was about the definition of "abuse potential" as the CSA uses it — a legal and pharmacological standard — and that psilocybin scores low on the defining criteria by any objective measure.^[1]

Criterion 2 — No Medical Use: Three Major Trials That Directly Contradict This

The "no accepted medical use" criterion is the most contested ground in the rescheduling debate, because the clinical evidence for psilocybin in depression accumulated rapidly between 2016 and 2022.

Three trials define the current evidentiary basis:

Davis et al. (2021, JAMA Psychiatry) — Johns Hopkins RCT

Davis and colleagues at Johns Hopkins conducted a randomized controlled trial of psilocybin-assisted therapy in 27 adults with major depressive disorder. At the four-week follow-up, 71% of participants met responder criteria for depression improvement, and 54% met remission criteria.^[3]

This trial, along with similar evidence from a preceding Johns Hopkins depression study, was part of the basis for the FDA granting psilocybin breakthrough therapy designation for treatment-resistant depression in 2018 and major depressive disorder in 2019. Breakthrough therapy designation is a formal FDA determination that "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint." The FDA does not grant this designation for substances with "no accepted medical use."^[3]

Carhart-Harris et al. (2021, NEJM) — Psilocybin vs. Escitalopram

Carhart-Harris and colleagues published a head-to-head randomized controlled trial comparing psilocybin to escitalopram, a standard SSRI antidepressant, in 59 patients with major depressive disorder.^[4]

Psilocybin matched escitalopram on the primary outcome (QIDS-SR-16 depression scale at six weeks). On six of the eight secondary measures, psilocybin outperformed escitalopram, including on measures of emotional processing, depression, anxiety, and quality of life. The trial was not powered to show superiority, and the authors appropriately framed the results as preliminary. But a head-to-head comparison in the New England Journal of Medicine, with results favoring the compound in question on multiple dimensions, is precisely the kind of clinical evidence the "no accepted medical use" criterion asserts does not exist.^[4]

Goodwin et al. (2022, NEJM) — COMPASS Phase 2b Trial

Goodwin and colleagues published results from the COMPASS Pathways Phase 2b dose-ranging trial in the New England Journal of Medicine. The trial enrolled 233 participants with treatment-resistant depression — the largest randomized psilocybin trial published to date.^[5]

A single 25mg psilocybin dose produced significant reductions in depression scores at three weeks compared to a 1mg control dose. This trial is the basis for COMPASS's ongoing Phase 3 program, targeting an NDA submission to the FDA. It provides the strongest large-scale randomized evidence to date for efficacy in the specific indication the FDA would evaluate for approval.^[5]

McClure-Begley and Roth, writing in Nature Reviews Drug Discovery in 2022, reviewed the clinical evidence across the psychedelic pharmacology field and concluded that the evidence for psilocybin in depression and addiction was "compelling enough to warrant regulatory reconsideration."^[7] The journal is the premier drug development review publication; the conclusion is notable for its venue.

For context on what FDA breakthrough therapy designation means in the rescheduling pathway, see Breakthrough Therapy Designation: What It Means for Psilocybin.

The Research Scale Problem: 134 Trials, Zero Approvals

Norring and colleagues published a systematic analysis in 2024 in Drug Design, Development and Therapy reviewing the complete scope of psilocybin clinical research on ClinicalTrials.gov.^[6]

Their findings: as of the analysis date, 134 interventional psilocybin trials across 54 potential indications had been registered. Average trial duration was 3.3 years. Total approvals: zero.

The zero-approval figure reflects a structural problem embedded in Schedule I status. Schedule I compounds face significantly higher barriers for clinical research than Schedule II or lower compounds: researchers must obtain a DEA Schedule I researcher license (a separate approval requirement from institutional review board approval), facilities must meet specific physical security standards, and the controlled substance must come from DEA-licensed manufacturers. The supply chain for Schedule I research is more restricted, more expensive, and more time-consuming than for lower-scheduled drugs. The administrative load of conducting Schedule I research selects for well-funded, institutionally capable teams — exactly the kind of infrastructure that most academic centers do not have readily available.^[6]

The result is that 134 trials have accumulated evidence across depression, addiction, PTSD, anorexia, OCD, and over 50 other conditions — but none has progressed to the approval stage, partly because the approval pathway itself runs through an agency system that has not yet approved a Schedule I substance for therapeutic use through the standard NDA route.

Criterion 3 — No Safe Use Under Medical Supervision: What the Clinical Record Shows

The "no accepted safety" criterion is the most difficult to defend as applied to psilocybin given the existing trial data.

Johnson and colleagues noted in their 2018 8-factor analysis that adverse events in clinical psilocybin trials are primarily psychological — transient anxiety, confusion, dysphoria — and that these risks can be substantially mitigated through screening, preparation, and supervised session settings. Serious physical adverse events attributable to psilocybin in clinical settings are rare. No confirmed deaths attributable to psilocybin toxicity have been documented in human trials.^[1]

McClure-Begley and Roth identified the actual safety challenges in their 2022 Nature Reviews analysis: they involve standardization of protocols, training requirements for session facilitators, screening criteria for contraindicated populations (personal or family history of psychosis or bipolar I), and the complexity of informed consent for novel psychological experiences. These are regulatory and training challenges — the challenges of implementing a new treatment category, not evidence that psilocybin cannot be used safely under supervision at all.^[7]

In other words, the clinical evidence suggests the safety challenges are manageable within a clinical framework. They are not evidence of the absence of any safe clinical use.

The Growing Policy Gap: 36 State Bills and One National Approval

Siegel and colleagues published an analysis in JAMA Psychiatry in 2023 tracking state-level psychedelic legislative reform across the United States from 2019 through 2022.^[8]

The numbers document the direction of travel: five state-level psychedelic reform bills were introduced in 2019. By 2022, the count had reached 36. Across the period, 25 states considered 74 reform bills. Oregon, which passed a psilocybin services law in 2020, reduced psilocybin-related arrests 87% following decriminalization. Siegel's analytic model projected that the majority of states would have legalized some form of psychedelic use by 2033 to 2037, assuming continuation of then-current trends.^[8]

The state-level momentum is occurring while federal Schedule I status remains. Individual cities have decriminalized psilocybin. Oregon and Colorado have created state-regulated psilocybin services frameworks. The FDA has granted two breakthrough therapy designations for depression and a de facto clinical development pathway through the COMPASS program.

In February 2023, Australia's Therapeutic Goods Administration became the first national drug regulator to approve psilocybin for clinical use in patients with treatment-resistant depression — a reclassification in a major regulatory peer nation that occurs under the "no medical use" classification the US currently maintains.

The gap between the federal Schedule I criteria and the clinical evidence, the international regulatory landscape, and state-level policy direction is the context within which the federal rescheduling debate is occurring. What the three rescheduling pathways look like — FDA approval triggering mandatory DEA action, DEA administrative petition, and congressional legislation — is covered in Federal Psilocybin Reform Efforts: Current Bills and Proposals and Psilocybin and Schedule I: The Legal History and Path to Rescheduling.

The Bottom Line

Psilocybin's Schedule I status rests on three criteria — high abuse potential, no accepted medical use, and no safe use under supervision — each of which is now contested by substantial clinical evidence. Johnson et al. (2018) applied the statutory abuse potential analysis and concluded it does not support Schedule I placement. Two trials in the New England Journal of Medicine and a Johns Hopkins RCT in JAMA Psychiatry established depression efficacy; the FDA granted two breakthrough therapy designations based on this line of evidence. McClure-Begley and Roth (2022) characterized the safety challenges as implementable clinical framework questions rather than fundamental barriers. Norring et al. (2024) documented 134 registered trials across 54 indications with zero marketing approvals — a direct consequence of the research barriers the current classification creates.

Frequently Asked Questions

Why is psilocybin illegal if it has medical benefits?

Psilocybin is classified as Schedule I under the 1970 Controlled Substances Act, which was enacted before modern clinical research methods existed for psychedelics. The classification requires that a substance have high abuse potential, no accepted medical use, and no safe clinical use. Johnson et al. (2018) analyzed psilocybin against all eight CSA statutory factors and concluded it has low abuse potential and no evidence of physical dependence. Two trials in the New England Journal of Medicine and an FDA breakthrough therapy designation directly challenge the "no medical use" criterion. The classification has not been updated to reflect this evidence.

What is the evidence for psilocybin's medical value?

The strongest evidence is in major depressive disorder and treatment-resistant depression. Goodwin et al. (2022, NEJM) conducted the largest randomized trial to date with 233 participants and found significant depression reductions at three weeks. Carhart-Harris et al. (2021, NEJM) compared psilocybin to escitalopram head-to-head in 59 patients; psilocybin matched the primary outcome and outperformed on six secondary measures. Davis et al. (2021, JAMA Psychiatry) found 71% of Johns Hopkins RCT participants met depression responder criteria at four weeks. These trials led the FDA to grant breakthrough therapy designation for both treatment-resistant and major depressive disorder.

Why hasn't the FDA approved psilocybin?

FDA approval requires completing Phase 3 clinical trials and submitting a New Drug Application (NDA). COMPASS Pathways, whose Phase 2b trial was published in NEJM in 2022 with 233 participants, is targeting an NDA submission. The process typically takes 10–15 years from Phase 1 to approval. Norring et al. (2024) documented 134 registered psilocybin trials with an average duration of 3.3 years and zero marketing approvals — reflecting both the length of the development timeline and the administrative barriers Schedule I status creates for research.

Is psilocybin dangerous enough to be Schedule I?

The pharmacological evidence suggests no. Nichols (2016) documented in Pharmacological Reviews that psilocybin has no known lethal dose in humans and produces no physical withdrawal syndrome. Johnson et al. (2018) applied the CSA's statutory safety criteria and concluded psilocybin does not meet the Schedule I safety threshold. McClure-Begley and Roth (2022, Nature Reviews Drug Discovery) identified the real clinical risks as protocol standardization and training requirements — challenges of clinical implementation, not fundamental safety barriers.

What would it take to make psilocybin legal?

Three federal pathways exist: FDA approval of a specific indication (which would trigger mandatory DEA rescheduling), a DEA administrative rescheduling petition currently under HHS review as of 2025, and direct Congressional legislation. At the state level, Siegel et al. (2023) documented 74 reform bills across 25 states in the period 2019–2022, with Oregon and Colorado creating regulated psilocybin services frameworks. Australia's Therapeutic Goods Administration approved psilocybin for treatment-resistant depression in 2023, providing the first national regulatory precedent.

Has psilocybin been proven to treat depression?

The clinical evidence supports a strong preliminary case, but "proven" depends on the regulatory standard. For FDA approval, Phase 3 data from adequately powered randomized controlled trials is required — that process is ongoing. For scientific evidence of efficacy, two NEJM-published trials and multiple other randomized studies have shown significant depression improvements. The FDA granted breakthrough therapy designation for treatment-resistant depression and major depressive disorder based on this body of evidence — a designation that formally acknowledges preliminary evidence of substantial clinical benefit.

Sources & References

1. 1RTHM-00514·Johnson, Matthew W et al. (2018). “The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act..” Neuropharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00439·Nichols, David E (2016). “Psychedelics..” Pharmacological reviews.Study breakdown →PubMed →↩
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6RTHM-01959·Norring, Sarah A et al. (2024). “The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov..” Drug design.Study breakdown →PubMed →↩
7. 7RTHM-00787·McClure-Begley, Tristan D et al. (2022). “The promises and perils of psychedelic pharmacology for psychiatry..” Nature reviews. Drug discovery.Study breakdown →PubMed →↩
8. 8RTHM-01791·Siegel, Joshua S et al. (2023). “Psychedelic Drug Legislative Reform and Legalization in the US..” JAMA psychiatry.Study breakdown →PubMed →↩